tetano
Editor, Senior Moderator
Wien Klin Wochenschr
. 2020 Aug 10.
doi: 10.1007/s00508-020-01720-y. Online ahead of print.
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort
Mario Karolyi[SUP] 1 [/SUP], Erich Pawelka[SUP] 2 [/SUP], Theresa Mader[SUP] 2 [/SUP], Sara Omid[SUP] 2 [/SUP], Hasan Kelani[SUP] 2 [/SUP], Sarah Ely[SUP] 3 [/SUP], Bernd Jilma[SUP] 3 [/SUP], Sebastian Baumgartner[SUP] 2 [/SUP], Hermann Laferl[SUP] 2 [/SUP], Clemens Ott[SUP] 2 [/SUP], Marianna Traugott[SUP] 2 [/SUP], Michael Turner[SUP] 2 [/SUP], Tamara Seitz[SUP] 2 [/SUP], Christoph Wenisch[SUP] 2 [/SUP], Alexander Zoufaly[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a high mortality. To date no trial comparing hydroxychloroquine (HCQ) and lopinavir/ritonavir (LPV/RTV) has been performed.
Methods: Hospitalized patients ≥18 years old with severe coronavirus disease 2019 (COVID-19) were treated with either HCQ or LPV/RTV if they had either respiratory insufficiency (SpO[SUB]2[/SUB] ≤ 93% on room air or the need for oxygen insufflation) or bilateral consolidations on chest X‑ray and at least 2 comorbidities associated with poor COVID-19 prognosis. Outcomes investigated included in-hospital mortality, intensive care unit (ICU) admission, length of stay, PCR (polymerase chain reaction) negativity and side effects of treatment.
Results: Of 156 patients (41% female) with a median age of 72 years (IQR 55.25-81) admitted to our department, 67 patients fulfilled the inclusion criteria (20 received HCQ, 47 LPV/RTV). Groups were comparable regarding most baseline characteristics. Median time from symptom onset to treatment initiation was 8 days and was similar between the groups (p = 0.727). There was no significant difference (HCQ vs. LPV/RTV) in hospital mortality (15% vs. 8.5%, p = 0.418), ICU admission rate (20% vs. 12.8%, p = 0.470) and length of stay (9 days vs. 11 days, p = 0.340). A PCR negativity from nasopharyngeal swabs was observed in approximately two thirds of patients in both groups. Side effects led to treatment discontinuation in 15% of patients in the LPV/RTV group.
Conclusion: No statistically significant differences were observed in outcome parameters in patients treated with HCQ or LPV/RTV but patients in the LPV/RTV group showed a numerically lower hospital mortality rate. Additionally, in comparison to other studies we demonstrated a lower mortality in patients treated with LPV/RTV despite having similar patient groups, perhaps due to early initiation of treatment.
Keywords: Austria; Outcome; Real world data; SARS-CoV-2; Treatment.
. 2020 Aug 10.
doi: 10.1007/s00508-020-01720-y. Online ahead of print.
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort
Mario Karolyi[SUP] 1 [/SUP], Erich Pawelka[SUP] 2 [/SUP], Theresa Mader[SUP] 2 [/SUP], Sara Omid[SUP] 2 [/SUP], Hasan Kelani[SUP] 2 [/SUP], Sarah Ely[SUP] 3 [/SUP], Bernd Jilma[SUP] 3 [/SUP], Sebastian Baumgartner[SUP] 2 [/SUP], Hermann Laferl[SUP] 2 [/SUP], Clemens Ott[SUP] 2 [/SUP], Marianna Traugott[SUP] 2 [/SUP], Michael Turner[SUP] 2 [/SUP], Tamara Seitz[SUP] 2 [/SUP], Christoph Wenisch[SUP] 2 [/SUP], Alexander Zoufaly[SUP] 2 [/SUP]
Affiliations
- PMID: 32776298
- DOI: 10.1007/s00508-020-01720-y
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a high mortality. To date no trial comparing hydroxychloroquine (HCQ) and lopinavir/ritonavir (LPV/RTV) has been performed.
Methods: Hospitalized patients ≥18 years old with severe coronavirus disease 2019 (COVID-19) were treated with either HCQ or LPV/RTV if they had either respiratory insufficiency (SpO[SUB]2[/SUB] ≤ 93% on room air or the need for oxygen insufflation) or bilateral consolidations on chest X‑ray and at least 2 comorbidities associated with poor COVID-19 prognosis. Outcomes investigated included in-hospital mortality, intensive care unit (ICU) admission, length of stay, PCR (polymerase chain reaction) negativity and side effects of treatment.
Results: Of 156 patients (41% female) with a median age of 72 years (IQR 55.25-81) admitted to our department, 67 patients fulfilled the inclusion criteria (20 received HCQ, 47 LPV/RTV). Groups were comparable regarding most baseline characteristics. Median time from symptom onset to treatment initiation was 8 days and was similar between the groups (p = 0.727). There was no significant difference (HCQ vs. LPV/RTV) in hospital mortality (15% vs. 8.5%, p = 0.418), ICU admission rate (20% vs. 12.8%, p = 0.470) and length of stay (9 days vs. 11 days, p = 0.340). A PCR negativity from nasopharyngeal swabs was observed in approximately two thirds of patients in both groups. Side effects led to treatment discontinuation in 15% of patients in the LPV/RTV group.
Conclusion: No statistically significant differences were observed in outcome parameters in patients treated with HCQ or LPV/RTV but patients in the LPV/RTV group showed a numerically lower hospital mortality rate. Additionally, in comparison to other studies we demonstrated a lower mortality in patients treated with LPV/RTV despite having similar patient groups, perhaps due to early initiation of treatment.
Keywords: Austria; Outcome; Real world data; SARS-CoV-2; Treatment.